guest ::
| Home > Publications database > Expanding our understanding of ovarian cancer risk: the role of incomplete pregnancies. > print |
| Home > Publications database > Expanding our understanding of ovarian cancer risk: the role of incomplete pregnancies. > print |
| 001 | 157423 | ||
| 005 | 20240229133507.0 | ||
| 024 | 7 | _ | |a 10.1093/jnci/djaa099 |2 doi |
| 024 | 7 | _ | |a pmid:32766851 |2 pmid |
| 024 | 7 | _ | |a 0027-8874 |2 ISSN |
| 024 | 7 | _ | |a 0198-0157 |2 ISSN |
| 024 | 7 | _ | |a 1460-2105 |2 ISSN |
| 024 | 7 | _ | |a altmetric:87951987 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2020-01618 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Lee, Alice W |b 0 |
| 245 | _ | _ | |a Expanding our understanding of ovarian cancer risk: the role of incomplete pregnancies. |
| 260 | _ | _ | |a Oxford |c 2021 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1617968081_17265 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2021 Mar 1;113(3):301-308 |
| 520 | _ | _ | |a Parity is associated with decreased risk of invasive ovarian cancer; however, the relationship between incomplete pregnancies and invasive ovarian cancer risk is unclear. This relationship was examined using 15 case-control studies from the Ovarian Cancer Association Consortium (OCAC). Histotype-specific associations, which have not been examined previously with large sample sizes, were also evaluated.A pooled analysis of 10,470 invasive epithelial ovarian cancer cases and 16,942 controls was conducted. Odds ratios and 95% confidence intervals for the association between incomplete pregnancies and invasive epithelial ovarian cancer were estimated using logistic regression. All models were conditioned on OCAC study, race/ethnicity, age, and education level, and adjusted for number of complete pregnancies, oral contraceptive use, and history of breastfeeding. The same approach was used for histotype-specific analyses.Ever having an incomplete pregnancy was associated with a 16% reduction in ovarian cancer risk (OR = 0.84, 95% CI = 0.79 to 0.89). There was a trend of decreasing risk with increasing number of incomplete pregnancies (two-sided Ptrend <.001). An inverse association was observed for all major histotypes; it was strongest for clear cell ovarian cancer.Incomplete pregnancies are associated with a reduced risk of invasive epithelial ovarian cancer. Pregnancy, including incomplete pregnancy, was associated with a greater reduction in risk of clear cell ovarian cancer, but the result was broadly consistent across histotypes. Future work should focus on understanding the mechanisms underlying this reduced risk. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |x 0 |f POF IV |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Rosenzweig, Stacey |b 1 |
| 700 | 1 | _ | |a Wiensch, Ashley |b 2 |
| 700 | 1 | _ | |a Group, Australian Ovarian Cancer Study |b 3 |e Collaboration Author |
| 700 | 1 | _ | |a Ramus, Susan J |b 4 |
| 700 | 1 | _ | |a Menon, Usha |b 5 |
| 700 | 1 | _ | |a Gentry-Maharaj, Aleksandra |b 6 |
| 700 | 1 | _ | |a Ziogas, Argyrios |b 7 |
| 700 | 1 | _ | |a Anton-Culver, Hoda |b 8 |
| 700 | 1 | _ | |a Whittemore, Alice S |b 9 |
| 700 | 1 | _ | |a Sieh, Weiva |b 10 |
| 700 | 1 | _ | |a Rothstein, Joseph H |b 11 |
| 700 | 1 | _ | |a McGuire, Valerie |b 12 |
| 700 | 1 | _ | |a Wentzensen, Nicolas |b 13 |
| 700 | 1 | _ | |a Bandera, Elisa V |b 14 |
| 700 | 1 | _ | |a Qin, Bo |b 15 |
| 700 | 1 | _ | |a Terry, Kathryn L |b 16 |
| 700 | 1 | _ | |a Cramer, Daniel W |b 17 |
| 700 | 1 | _ | |a Titus, Linda |b 18 |
| 700 | 1 | _ | |a Schildkraut, Joellen M |b 19 |
| 700 | 1 | _ | |a Berchuck, Andrew |b 20 |
| 700 | 1 | _ | |a Goode, Ellen L |b 21 |
| 700 | 1 | _ | |a Kjaer, Susanne K |b 22 |
| 700 | 1 | _ | |a Jensen, Allan |b 23 |
| 700 | 1 | _ | |a Jordan, Susan J |b 24 |
| 700 | 1 | _ | |a Ness, Roberta B |b 25 |
| 700 | 1 | _ | |a Modugno, Francesmary |b 26 |
| 700 | 1 | _ | |a Moysich, Kirsten |b 27 |
| 700 | 1 | _ | |a Thompson, Pamela J |b 28 |
| 700 | 1 | _ | |a Goodman, Marc T |b 29 |
| 700 | 1 | _ | |a Carney, Michael E |b 30 |
| 700 | 1 | _ | |a Chang-Claude, Jenny |0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253 |b 31 |u dkfz |
| 700 | 1 | _ | |a Rossing, Mary Anne |b 32 |
| 700 | 1 | _ | |a Harris, Holly R |b 33 |
| 700 | 1 | _ | |a Doherty, Jennifer Anne |b 34 |
| 700 | 1 | _ | |a Risch, Harvey A |b 35 |
| 700 | 1 | _ | |a Khoja, Lilah |b 36 |
| 700 | 1 | _ | |a Alimujiang, Aliya |b 37 |
| 700 | 1 | _ | |a Phung, Minh Tung |b 38 |
| 700 | 1 | _ | |a Brieger, Katharine |b 39 |
| 700 | 1 | _ | |a Mukherjee, Bhramar |b 40 |
| 700 | 1 | _ | |a Pharoah, Paul D P |b 41 |
| 700 | 1 | _ | |a Wu, Anna H |b 42 |
| 700 | 1 | _ | |a Pike, Malcolm C |b 43 |
| 700 | 1 | _ | |a Webb, Penelope M |b 44 |
| 700 | 1 | _ | |a Pearce, Celeste Leigh |b 45 |
| 773 | _ | _ | |a 10.1093/jnci/djaa099 |g p. djaa099 |0 PERI:(DE-600)1465951-7 |n 3 |p 301-308 |t Journal of the National Cancer Institute |v 113 |y 2021 |x 1460-2105 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:157423 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 31 |6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253 |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Cancer risk factors and prevention |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2020-01-09 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-01-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |d 2020-01-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2020-01-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-01-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2020-01-09 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |d 2020-01-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-01-09 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |d 2020-01-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-01-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2020-01-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2020-01-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2020-01-09 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b JNCI-J NATL CANCER I : 2018 |d 2020-01-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-01-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2020-01-09 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2020-01-09 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b JNCI-J NATL CANCER I : 2018 |d 2020-01-09 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|